10-Q: GRI Bio Q2 2025: Losses Widen, Going Concern Warning

GRI Bio reports increased net losses and a going concern warning, despite recent capital raises and progress in its lead clinical program.

Summary

• GRI Bio reported a net loss of $2.9 million for the three months ended June 30, 2025, an increase from $2.3 million for the same period in 2024.
• For the six months ended June 30, 2025, the net loss was $5.9 million, up from $4.1 million in the prior year period.
• Research and development expenses significantly increased to $1.9 million for Q2 2025 (from $0.9 million in Q2 2024) and $3.5 million for the six months ended June 30, 2025 (from $1.8 million in the prior year period), primarily due to the GRI-0621 development program.
• General and administrative expenses decreased to $1.0 million for Q2 2025 (from $1.4 million in Q2 2024) but slightly increased to $2.4 million for the six months ended June 30, 2025 (from $2.3 million in the prior year period).
• The company had $5.1 million in cash and cash equivalents as of June 30, 2025, and an accumulated deficit of $45.7 million.
• Management believes existing cash will fund operations into the fourth quarter of 2025, but there is substantial doubt about the company's ability to continue as a going concern.
• Enrollment for the Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) was completed in July 2025, with topline results expected in Q3 2025.
• The company completed an April 2025 public offering, raising $4.0 million in net proceeds (before $1.0 million offering expenses), and continued to raise capital through its At-The-Market (ATM) offering, selling 582,554 shares for $0.8 million net proceeds in Q2 2025.

Sentiment

Score: 3

Explanation: The company is making progress in its clinical trials and has recently raised capital, which are positive. However, the significant increase in net losses, the explicit 'going concern' warning, and the very short cash runway (into Q4 2025) indicate a precarious financial position and high operational risk.

Positives

• Enrollment for the Phase 2a biomarker study of GRI-0621 for Idiopathic Pulmonary Fibrosis (IPF) was completed in July 2025.
• Preliminary data from GRI-0621 trials suggest an anti-fibrotic effect, with decreases in fibrosis formation biomarkers and increases in fibrosis resolution biomarkers.
• No safety concerns have been observed by the Independent Data Monitoring Committee (IDMC) review for GRI-0621.
• Successfully raised $4.0 million in net proceeds from the April 2025 public offering and an additional $0.8 million net proceeds from the ATM offering during Q2 2025.

Negatives

• Net loss increased to $2.9 million for the three months ended June 30, 2025, from $2.3 million in the prior year period.
• Net loss for the six months ended June 30, 2025, increased to $5.9 million from $4.1 million in the prior year period.
• Accumulated deficit reached $45.7 million as of June 30, 2025.
• Substantial doubt exists about the company's ability to continue as a going concern beyond the fourth quarter of 2025 without additional funding.
• Development of GRI-0803 is limited pending additional funding.
• Identified a material weakness in internal control over financial reporting related to inaccurate computation of a non-cash deemed dividend.

Risks

• Ability to continue as a going concern is dependent on raising additional capital, with no assurances such financing will be available on acceptable terms or in necessary amounts.
• If unable to obtain additional financing, the company may be forced to reduce or discontinue operations, delay or eliminate development programs, or relinquish technology rights.
• Attempting to secure additional financing may divert management's time and attention from core business activities.
• The company has not generated significant revenues from operations since inception and does not expect to do so in the foreseeable future.
• The company expects to continue to incur significant and increasing operating losses.
• Material weakness in internal control over financial reporting related to inaccurate computation of non-cash deemed dividend.

Future Outlook

The company expects to continue incurring significant operating losses for the foreseeable future and does not anticipate generating product revenue until successful development, regulatory approval, and commercialization of its product candidates. Existing cash and cash equivalents are projected to fund operating expenses and capital expenditure requirements into the fourth quarter of 2025. The company intends to raise additional capital through equity securities and/or debt arrangements to fund ongoing operations, including planned clinical trials for GRI-0621 and GRI-0803, and discovery programs. An IND application for GRI-0803's Phase 1a/1b trial is expected to be filed in 2026, subject to funding and IND clearance. Topline results from the GRI-0621 Phase 2a biomarker study are expected in the third quarter of 2025.

Management Comments

• Our goal is to be an industry leader in developing therapies to treat these diseases and to improve the lives of patients suffering from such diseases.
• Based on our current operating plan, our existing cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025.
• The Company's ability to continue as a going concern is dependent on its ability to raise additional capital to fund its business activities, including its research and development program.
• If the Company is not able to obtain additional financing on acceptable terms and in the amounts necessary to fully fund its future operating requirements, it may be forced to reduce or discontinue its operations entirely.
• We expect our research and development expenses to increase over the next several years as we conduct our planned clinical and preclinical activities for our product candidates.
• We expect our general and administrative expenses will continue to increase as we incur costs associated with being a public company.
• Notwithstanding this material weakness, our financial statements contained in this Quarterly Report on Form 10-Q fairly present our financial position, results of operations and cash flows for the periods covered by this report in all material respects.

Industry Context

GRI Bio operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on inflammatory, fibrotic, and autoimmune disorders. Its lead candidate, GRI-0621, targets Idiopathic Pulmonary Fibrosis (IPF), a severe lung disease with limited treatment options that have significant side effects and no proven survival benefit. The company notes that only two drugs have been approved for lupus in the past 50 years, highlighting the significant unmet medical need in this area, which GRI-0803 aims to address. The company's strategy to focus resources on GRI-0621 while limiting GRI-0803 development due to funding constraints is a common challenge for clinical-stage biotechs. The reliance on equity financing and ATM offerings is typical for companies in this stage that have not yet generated revenue.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against.
• The company's financial position, characterized by increasing net losses and a 'going concern' warning, is common for clinical-stage biopharmaceutical companies that are pre-revenue and heavily investing in R&D.
• The significant increase in R&D expenses for GRI-0621's development program is consistent with a company advancing a lead candidate into later-stage clinical trials.
• The use of public offerings and At-The-Market (ATM) facilities for capital raising is a standard practice for small-cap biotechs to fund operations and clinical development.

Management Changes

Corporate Governance

Legal Proceedings

• Not currently a party to any material legal proceedings.
• Not aware of any pending or threatened legal proceeding that could have an adverse effect on business, operating results, or financial condition.

Stakeholder Impact

• Shareholders: Significant dilution from recent and ongoing equity offerings (e.g., April 2025 offering, ATM offering). Risk of further dilution due to future capital raises. Share price highly sensitive to clinical trial results and funding news. Substantial doubt about going concern poses significant risk to investment value.
• Employees: Continued employment and compensation are dependent on the company's ability to secure additional funding.
• Customers/Patients: Development of potential therapies (GRI-0621 for IPF, GRI-0803 for autoimmune disorders) is critical for patients suffering from these serious diseases. Delays or cessation of operations due to funding issues would negatively impact patient access to these potential treatments.
• Creditors: Risk associated with the company's going concern status and reliance on future equity raises.

Next Steps

• Topline results from the Phase 2a biomarker study for GRI-0621 are expected in the third quarter of 2025.
• Subject to additional funding and IND clearance, the company intends to evaluate GRI-0803 in a Phase 1a and 1b trial initially targeting SLE.
• File an IND application for GRI-0803's Phase 1a/1b trial in 2026.
• Continue to evaluate indications to select the best fit for further development of the GRI-0803 program.
• Implement remediation plan for the identified material weakness in internal controls, including continued engagement of third-party professionals and enhanced documentation.

Key Dates

Recommendation

The company faces substantial doubt about its ability to continue as a going concern, with cash only sufficient into Q4 2025. Net losses have significantly increased, and while clinical trial progress is noted, the immediate financial instability and continuous need for dilutive capital raises present extreme risk. The material weakness in internal controls adds to governance concerns. Without a clear path to sustained funding beyond the near term, the investment carries very high risk of significant capital loss.

Keywords

Biopharmaceutical, Clinical-stage, Idiopathic Pulmonary Fibrosis, IPF, Autoimmune disorders, Systemic Lupus Erythematosus, SLE, Multiple Sclerosis, MS, GRI-0621, GRI-0803, iNKT cells, dNKT cells, Drug development, SEC filing, 10-Q, Biotechnology, Clinical trials, Capital raise, Warrants, Public offering, ATM offering, Going concern